AbbVie Q2 IPR&D expenses to lower EPS by $0.52 (NYSE:ABBV)

Abbvie

vzphotos

AbbVie (NYSE:ABBV) said Wednesday it plans on reporting acquired IPR&D and milestone expenses of $937M on a pre-tax basis for Q2, which will reduce earnings per share on both a GAAP and non-GAAP basis by $0.52.

In an SEC filing